RT Journal Article
SR Electronic
T1 The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.05.21251219
DO 10.1101/2021.02.05.21251219
A1 Riccardo Levi
A1 Leonardo Ubaldi
A1 Chiara Pozzi
A1 Giovanni Angelotti
A1 Maria Teresa Sandri
A1 Elena Azzolini
A1 Michela Salvatici
A1 Victor Savevski
A1 Alberto Mantovani
A1 Maria Rescigno
YR 2021
UL http://medrxiv.org/content/early/2021/07/05/2021.02.05.21251219.abstract
AB The factors involved in the persistence of antibodies to SARS-CoV-2 are unknown. We evaluated the antibody response to SARS-CoV-2 in personnel from 10 healthcare facilities and its association with individuals’ characteristics and COVID-19 symptoms in an observational study. We enrolled 4735 subjects (corresponding to 80% of all personnel) for three time points over a period of 8-10 months. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach. In individuals positive for IgG (≥ 12 AU/mL) at the beginning of the study, we found an increase [p= 0.0002] in antibody response in symptomatic subjects, particularly with anosmia/dysgeusia (OR 2.75, 95% CI 1.753 – 4.301), in a multivariate logistic regression analysis. This may be linked to the lingering of SARS-CoV-2 in the olfactory bulb.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04387929Funding StatementThis work was partially supported by a philantropic donation by Dolce & Gabbana, by the Italian Ministry of Health (Ricerca corrente) and by Fondazione Humanitas per la Ricerca.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This observational study has been approved by the international review board of Istituto Clinico Humanitas for all participating institutes (clinicaltrial.gov NCT04387929).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesHumanitas metadata are deposited in Institutional Zenodo community named IRCCS Humanitas Research Hospital & Humanitas University. The dataset and the code are available at the link https://zenodo.org/record/4528974#.YCONKXnSJaQ with restricted license however available upon request. https://zenodo.org/record/4528974#.YCONKXnSJaQ